1-3 of 3
Mark J. Raftery
Close
Sort by
Journal Articles

Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and Sumoylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Peter Truong, Sylvie Shen, Swapna Joshi, Ali Afrasiabi, Ling Zhong, Mark J. Raftery, Jonas Larsson, Richard B. Lock, Carl R. Walkley, Hamid Alinejad Rokny, Julie A.I. Thoms, Christopher J. Jolly, John E. Pimanda
Journal: Blood
Blood (2022) 140 (Supplement 1): 220–221.
https://doi.org/10.1182/blood-2022-165713
Published: 2022
Journal Articles

Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling

Sibasish Dolai, PhD, Keith CS Sia, BSc(Hons), Alissa K Robbins, BSc(Hons), Ling Zhong, PhD, Sue Heatley, PhD, Tiffaney Vincent, BS, Falko Hochgräfe, PhD, Raushan T. Kurmasheva, PhD, Deborah L White, PhD FFSc (RCPA), Peter J. Houghton, PhD, Malcolm A. Smith, MD PhD, David T. Teachey, MD, Roger J Daly, PhD, Mark J Raftery, PhD, Richard B. Lock, PhD
Journal: Blood
Blood (2014) 124 (21): 969.
https://doi.org/10.1182/blood.V124.21.969.969
Published: 2014
Journal Articles

Beta 2 glycoprotein I is a substrate of thiol oxidoreductases

Freda H. Passam, Soheila Rahgozar, Miao Qi, Mark J. Raftery, Jason W. H. Wong, Kumiko Tanaka, Yiannis Ioannou, Jing Yun Zhang, Rosalie Gemmell, Jian Chen Qi, Bill Giannakopoulos, Will E. Hughes, Philip J. Hogg, Steven A. Krilis
Journal: Blood
Blood (2010) 116 (11): 1995–1997.
https://doi.org/10.1182/blood-2010-02-271494
Published: 2010